Murilo Montanari de Matos

Murilo Montanari de Matos

Auto-generated profile, based on publicly available information

Murilo Montanari de Matos

Serviço Nacional de Aprendizagem Industrial, Brazil

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2017
Verified
Conference Paper
Open access
PDF file
MMMurilo Montanari de Matos
Murilo Montanari de Matos
SQSérgio Robles Reis de Queiroz
Sérgio Robles Reis de Queiroz
The pharmaceutical industry has undergone several changes and challenges, nowadays the industry is facing a R&D productivity crises. A series of questions arise from this fact, two of it can be highlighted as important for this study that are: how the industry is dealing with this crises? Does it bring new features to the sector? The answer that this article proposes it is also our argument, that is: the solution sought by the industry is both technological and organizational and it resides outside the large pharmaceutical enterprise's borders, therefore, those companies are using strategies, especially acquisitions of small biotech enterprises to incorporate new technologies that, arguably, will increase the large enterprise's innovative output. Therefore this article objective is to prove the argument. In order to achieve the objective proposed this work proposes to combine bibliographic research on the economic literature and the specialized literature on drug discovery techniques to describe this activity evolution, in addition, some important data will be present to sustain the assertions made. As a conclusion the article shows that the R&D activities evolution has created a biotechnology trajectory, in the pharmaceutical companies, that made the incorporation of small biotech enterprises a recurrent strategy.

4 June 2019 in Revista Economia Ensaios
Verified
Journal Article
Closed access
MMMurilo Montanari De Matos
Murilo Montanari De Matos
Este artigo propõe analisar, com base em dados de patentes, um conjunto de fusões e aquisições (F&A) entre grandes empresas farmacêuticas e pequenas empresas de biotecnologia, no período de 2005 a 2012. O artigo começa discutindo o papel das F&A motivadas por aspectos tecnológicos e, dessa forma, estabelece a importância das pequenas empresas como fontes de novas tecnologias às grandes empresas. Por meio desta discussão, é mostrada a crescente relação entre as biotecnologias e o processo inovativo na indústria farmacêutica, que leva à incorporação das pequenas empresas de biotecnologia. Assim, o artigo deixa evidente que as aquisições são uma importante fonte de novas tecnologias para as grandes empresas. Como conclusão, se observa que as aquisições geram um relevante output tecnológico às grandes empresas farmacêuticas tornando as pequenas empresas fontes de novas tecnologias em etapas iniciais de desenvolvimento.

3 August 2020 in Revista Brasileira de Inovação
Verified
Journal Article
Open access
PDF file
MMMurilo Montanari Matos
Murilo Montanari Matos
This article focuses on the incorporation of knowledge conducted by large pharmaceutical corporations through the acquisition of small enterprises. The objective was to evidence to which degree the incorporation of knowledge is performed by a sample of 8 large pharmaceutical companies. In order to do this, we rely on qualitative methods, based on a sample of eight companies and 54 small enterprises they acquired in the period from 2005 to 2012. From the sample we compiled the patents granted to the small firms within the USPTO. The analysis conducted develops two central actions. The first is theinventor’s usage, defined as the small enterprises inventors, which when incorporated by large pharmaceutical corporations started to develop patents through the acquiring larger company. The second is the incorporation of research trajectories, which means how inventors cite their past work as they are incorporated into the larger companies. This article concludes that the incorporation of inventors is a relevant strategy among the large companies studied so that these companies can incorporate external knowledge bases from the acquired smaller enterprises; however, just a few inventors are incorporated, which shows that just a small group of people conducts innovative research for large companies. This article contribution was to categorically evidence the incorporation of knowledge through new metrics, being them: inventor’s usage and research trajectory incorporation.


1 January 2022 in RAE: Revista de Administracao de Empresas
Verified
Journal Article
Open access
MMMurilo Montanari de Matos
Murilo Montanari de Matos
AAAna Paula Macedo de Avellar
Ana Paula Macedo de Avellar
This article focuses on the acquisition of small pharmaceutical firms (SPHF) by large pharmaceutical firms (LPHF). LPHFs enlarge their own knowledge base by incorporating their target’s knowledge base. Given this scenario we pose the question: Is it possible to link knowledge acquired via an acquisition to technological development? In order to answer this question we developed an approach that allows the impact of a target’s knowledge base to be observed in the acquirer’s own knowledge base. This objective was achieved qualitatively, based on a sample of 8 LPHFs and 51 SPHFs. Our main conclusions were: (i) the dissemination of biotechnologies is boosted by acquisition; (ii) acquisitions have allowed the knowledge bases of LPHFs to assimilate their target’s knowledge bases; (iii) the target’s patents offer a great potential for developing technologies that are already dominated by the LPHF; and (iv) the “incorporation” of scientists from target companies allows LPHFs to internalize research lines. Our main contribution is to link knowledge base characteristics to potential directions taken in the technological development process.

15 November 2013 in Revista Gestão & Conexões
Verified
Journal Article
Closed access
PDF file
MMMurilo Montanari De Matos
Murilo Montanari De Matos
SQSérgio Robles Reis De Queiroz
Sérgio Robles Reis De Queiroz
DOI: http://dx.doi.org/10.13071/regec.2317-5087.2013.2.2.4555.9-31 The Brazilian local computer producers have the largest market share, even competing with large global players. This article objective is to discuss how the national private enterprises can compete in complex markets, accumulating not only technological competences but non technological ones. First, the technological paradigm theory allows dividing the computer industry in two groups: the enterprises that control the paradigm core and then push forward the technological frontier; and the enterprises whose competences encompass the secondary paradigm elements. Second, thePositivo’s analyses shows that this enterprise’s competitiveness isn’t connected to its technological competences. Also the elements that keep the local industry competitive are related to the population income expansion experienced in Brazil and due to the enterprise extreme specialization in the lower income population. It is concluded that the Brazilian computer industry can be competitive without accumulation technological competences.